<SEC-DOCUMENT>0001104659-20-084443.txt : 20200717
<SEC-HEADER>0001104659-20-084443.hdr.sgml : 20200717
<ACCEPTANCE-DATETIME>20200717140045
ACCESSION NUMBER:		0001104659-20-084443
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20200708
FILED AS OF DATE:		20200717
DATE AS OF CHANGE:		20200717

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			GILEAD SCIENCES INC
		CENTRAL INDEX KEY:			0000882095
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38419
		FILM NUMBER:		201033439

	BUSINESS ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404
		BUSINESS PHONE:		6505743000

	MAIL ADDRESS:	
		STREET 1:		333 LAKESIDE DR
		CITY:			FOSTER CITY
		STATE:			CA
		ZIP:			94404

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Arcus Biosciences, Inc.
		CENTRAL INDEX KEY:			0001724521
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				473898435
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
		BUSINESS PHONE:		(510) 694-6200

	MAIL ADDRESS:	
		STREET 1:		3928 POINT EDEN WAY
		CITY:			HAYWARD
		STATE:			CA
		ZIP:			94545
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>a3.xml
<DESCRIPTION>3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2020-07-08</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001724521</issuerCik>
        <issuerName>Arcus Biosciences, Inc.</issuerName>
        <issuerTradingSymbol>RCUS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0000882095</rptOwnerCik>
            <rptOwnerName>GILEAD SCIENCES INC</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>333 LAKESIDE DRIVE</rptOwnerStreet1>
            <rptOwnerStreet2></rptOwnerStreet2>
            <rptOwnerCity>FOSTER CITY</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>94404</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>8163029</value>
                    <footnoteId id="F1"/>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Option to Purchase Common Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F4"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F2"/>
                <footnoteId id="F3"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <footnoteId id="F2"/>
                    <footnoteId id="F3"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Includes (i) 2,200,000 shares of common stock of Arcus Biosciences, Inc. (the &quot;Issuer&quot;) purchased in the Issuer's most recent public offering that closed on June 2, 2020 and (ii) the initial purchase of 5,963,029 shares of common stock of the Issuer pursuant to a Common Stock Purchase Agreement, dated May 27, 2020, between Gilead Sciences, Inc. and the Issuer (the &quot;Purchase Agreement&quot;).</footnote>
        <footnote id="F2">Includes the number of shares of common stock that would result in Gilead Sciences, Inc. holding 35% of the Issuer's then-outstanding common stock pursuant to a five-year option to purchase additional shares of common stock contained in the Purchase Agreement (the &quot;Option Shares&quot;).</footnote>
        <footnote id="F3">Based upon 56,982,788 shares of common stock of the Issuer issued and outstanding upon the closing of the Issuer's most recent public offering (assuming the underwriters have not exercised their option to purchase additional shares), as reported in the Issuer's prospectus dated May 28, 2020 filed with the Securities and Exchange Commission on May 29, 2020 pursuant to Rule 424(b)(5) under the Securities Act of 1933, as amended, (adjusted to account for the initial purchase of 5,963,029 shares of common stock pursuant to the Purchase Agreement and assuming the immediate exercise in full by Gilead Sciences, Inc. of its option to purchase the Option Shares) the number of Option Shares is currently equal to 21,335,395.</footnote>
        <footnote id="F4">The purchase price for the Option Shares will be equal to the greater of a 20% premium to market (based on a trailing five-day average closing price) at the time Gilead Sciences, Inc. exercises such option and $33.54 per share.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>Gilead Sciences, Inc. By: /s/ Andrew D. Dickinson</signatureName>
        <signatureDate>2020-07-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
